Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by GLOBALT Investments LLC GA

GLOBALT Investments LLC GA boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% during the 3rd quarter, Holdings Channel.com reports. The fund owned 1,067 shares of the biopharmaceutical company’s stock after purchasing an additional 16 shares during the quarter. GLOBALT Investments LLC GA’s holdings in Regeneron Pharmaceuticals were worth $1,122,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Capital International Investors raised its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after purchasing an additional 213,038 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after buying an additional 184,561 shares in the last quarter. International Assets Investment Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Regeneron Pharmaceuticals by 12.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock valued at $567,864,000 after acquiring an additional 59,769 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Regeneron Pharmaceuticals by 23.8% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after acquiring an additional 96,266 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.7 %

Shares of NASDAQ REGN opened at $762.00 on Tuesday. The business has a 50 day simple moving average of $977.55 and a 200 day simple moving average of $1,033.65. Regeneron Pharmaceuticals, Inc. has a 52 week low of $750.20 and a 52 week high of $1,211.20. The stock has a market cap of $83.74 billion, a price-to-earnings ratio of 18.86, a PEG ratio of 2.86 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. TD Cowen upped their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a research report on Friday. They issued an “outperform” rating and a $1,150.00 target price on the stock. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Citigroup began coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 14th. They set a “neutral” rating and a $895.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.